Amneal Pharmaceuticals, Inc. Class A Forecast, price target & analysts
Amneal Pharmaceuticals, Inc. Class A Target price 2026 - Analyst rating & recommendation
Amneal Pharmaceuticals, Inc. Class A Classifications & Recommendation
Amneal Pharmaceuticals, Inc. Class A Price Target
| Target Price | $21.42 |
| Price | $20.30 |
| Potential |
5.52%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Amneal Pharmaceuticals, Inc. Class A 2027 .
The average Amneal Pharmaceuticals, Inc. Class A target price is $21.42.
This is
5.52%
register free of charge
$26.25
29.31%
register free of charge
$16.16
20.39%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Amneal Pharmaceuticals, Inc. Class A to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Amneal Pharmaceuticals, Inc. Class A stock has an average upside potential 2027 of
5.52%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 3.02 | 3.22 |
| 8.05% | 6.57% | |
| EBITDA Margin | 20.59% | 24.60% |
| 1.60% | 19.49% | |
| Net Margin | 2.39% | 10.32% |
| 157.06% | 332.33% |
9 Analysts have issued a sales forecast Amneal Pharmaceuticals, Inc. Class A 2026 . The average Amneal Pharmaceuticals, Inc. Class A sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Amneal Pharmaceuticals, Inc. Class A EBITDA forecast 2026. The average Amneal Pharmaceuticals, Inc. Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Amneal Pharmaceuticals, Inc. Class A Analysts have issued a net profit forecast 2026. The average Amneal Pharmaceuticals, Inc. Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.22 | 1.04 |
| 157.89% | 372.73% | |
| P/E | 19.52 | |
| EV/Sales | 2.82 |
9 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast for earnings per share. The average Amneal Pharmaceuticals, Inc. Class A EPS is
This results in the following potential growth metrics and future valuations:
Amneal Pharmaceuticals, Inc. Class A...
Current Amneal Pharmaceuticals, Inc. Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 26 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Jul 15 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | May 20 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 26 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Jul 15 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
May 20 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
